RxDoctor Payments Data

Khalid Changal, MD

Interventional Cardiology · Sioux City, IANPI 1861846560

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (42.0%), food and beverage and grants — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Medtronic at 45.4% of the total. Reporting peaked in 2023 at $4,209 and has fallen 88.4% since, to $488 in 2025.

$6,679in general payments, 2019–2025

Across 70 payments — averaging $95.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$2K
  • Abiomed$347
  • Shockwave Medical, Inc$227
  • Bard Peripheral Vascular, Inc.$177
  • Asahi Intecc USA, Inc.$103
  • plus $392 from 10 others

What the payments were for

  • Grants$1,39821%
  • Travel & lodging$2,80542%
  • Food & beverage$2,19633%
  • Education$2804%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,679 in reported general payments places this provider in the 60th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$178,214
Medicare patients
1,344
Services billed
3,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$36,146
EntrestoSacubitril/Valsartan37$34,957
FarxigaDapagliflozin Propanediol19$15,796
JardianceEmpagliflozin17$11,259
Colchicine24$2,774
Ranolazine ErRanolazine17$1,152
Metoprolol Succinate123$1,106
Ezetimibe25$560
Atorvastatin Calcium69$483
ClopidogrelClopidogrel Bisulfate50$458
Rosuvastatin Calcium47$293
Isosorbide Mononitrate ErIsosorbide Mononitrate49$259
Lisinopril31$193
Spironolactone48$190
Pantoprazole Sodium17$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$36,14660 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 64 interventional cardiology providers in Iowa.

Other interventional cardiology in Sioux City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →